Related news from
Sat, 24 Oct 2026 01:28:19 +0000	Cencora's Q4 2026 Earnings: What to Expect Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.
Wed, 21 Oct 2026 11:30:00 +0000	Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology CONSHOHOCKEN, Pa. & FORT MYERS, Fla., October 21, 2026--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states.
Fri, 16 Oct 2026 15:55:39 +0000	Cencora (COR): 3 Reasons We Love This Stock Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per share while the index has gained 9.7%.
Fri, 16 Oct 2026 15:11:29 +0000	Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In? Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the business can generate. With cash flows in focus, recent gains invite a closer look at what the underlying economics of the company really support. Over the past 5 years Cencora has returned 192.4%, which puts a lot of accumulated optimism on the line if its future cash generation does not keep pace. Management has highlighted a pharmaceutical centric...
Sat, 24 Oct 2026 00:21:12 +0000	Is American Oncology Network (AONC) Fully Valued Following Cencora's $2.4b Buyout Deal? Cencora (COR) has moved to take control of American Oncology Network (OTCPK:AONC) by signing a deal to acquire the remaining 96% it does not own for an enterprise value of $2.4b. American Oncology Network’s share price has surged in recent weeks, with a 7 day and 30 day share price return of about 100% and a 1 year total shareholder return of 149.26%. This suggests the Cencora offer has sharply reset expectations around the stock’s value and risk profile. Spot similar healthcare momentum by...
Tue, 20 Oct 2026 21:35:02 +0000	AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Thu, 15 Oct 2026 14:36:05 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Mon, 12 Oct 2026 23:51:01 +0000	AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
Sun, 04 Oct 2026 14:34:57 +0000	Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Fri, 02 Oct 2026 12:00:00 +0000	Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.
Fri, 02 Oct 2026 09:42:03 +0000	2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Thu, 01 Oct 2026 22:41:02 +0000	AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Mon, 28 Sep 2026 13:18:36 +0000	1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Fri, 25 Sep 2026 21:22:01 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Sat, 24 Oct 2026 16:31:01 +0000	Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
Thu, 22 Oct 2026 22:15:02 +0000	Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
Tue, 20 Oct 2026 22:05:02 +0000	Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.
Tue, 06 Oct 2026 13:30:01 +0000	Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!